2013
TCT-20 Two-Year Clinical Follow-Up of the FIREHAWK Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent in the Treatment of Patients with De Novo Native Coronary Artery Lesions: The TARGET I Trial
Xu B, Gao R, Lansky A, Yang Y, Changsheng M, Han Y, Chen S, Li H, Zhang R, Fu G, Yuan Z, Huo Y, Li W, Zhao Y, Leon M. TCT-20 Two-Year Clinical Follow-Up of the FIREHAWK Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent in the Treatment of Patients with De Novo Native Coronary Artery Lesions: The TARGET I Trial. Journal Of The American College Of Cardiology 2013, 62: b7-b8. DOI: 10.1016/j.jacc.2013.08.748.Peer-Reviewed Original ResearchDe novo native coronary artery lesionsBiodegradable Polymer Sirolimus-Eluting StentNovo native coronary artery lesionsNative coronary artery lesionsCoronary artery lesionsSirolimus-Eluting StentsTreatment of patientsTwo-Year ClinicalAbluminal grooveArtery lesionsI trialPatientsClinicalLesionsStentsTrials
2009
Clinical and angiographic outcomes with an everolimus‐eluting stent in large coronary arteries: The SPIRIT III 4.0 mm registry
Gordon PC, Applegate RJ, Hermiller JB, Weinsier SB, Doostzadeh J, Cao S, Sudhir K, Lansky AJ, Stone GW. Clinical and angiographic outcomes with an everolimus‐eluting stent in large coronary arteries: The SPIRIT III 4.0 mm registry. Catheterization And Cardiovascular Interventions 2009, 75: 179-186. PMID: 19877267, DOI: 10.1002/ccd.22259.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryCardiovascular AgentsCoronary AngiographyCoronary StenosisDrug-Eluting StentsEverolimusFemaleHumansKaplan-Meier EstimateMaleMiddle AgedMyocardial InfarctionPaclitaxelPredictive Value of TestsProspective StudiesRegistriesRisk AssessmentSingle-Blind MethodSirolimusThrombosisTime FactorsTreatment OutcomeUnited StatesConceptsMajor adverse cardiac eventsTarget vessel failureSegment late lossSPIRIT III trialLarge coronary arteriesPaclitaxel-eluting stentsLate lossCoronary arteryIII trialsXIENCE VDe novo native coronary artery lesionsNovo native coronary artery lesionsNative coronary artery lesionsPE armSPIRIT IIIAdverse cardiac eventsCoronary artery lesionsAdverse clinical eventsAngiographic late lossEES patientsNoninferior ratesPrimary endpointAngiographic outcomesArtery lesionsCardiac events